CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-09-09 | GADICKE ANSBERT Director | Sale | −1,898 | $29.35 | $56K | 248,170 |
| 2021-09-09 | GADICKE ANSBERT Director | Sale | −13,727 | $29.35 | $403K | 7,674,449 |
| 2021-09-08 | Trigilio Jeffrey Chief Financial Officer | Option exercise | +15,000 | $4.30 | $65K | 17,250 |
| 2021-09-08 | Trigilio Jeffrey Chief Financial Officer | Sale | −5,487 | $27.83 | $153K | 11,763 |
| 2021-09-08 | Trigilio Jeffrey Chief Financial Officer | Sale | −9,513 | $28.85 | $274K | 2,250 |
| 2021-09-08 | Trigilio Jeffrey Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −15,000 | 237,891 | ||
| 2021-09-08 | Baeuerle Patrick See Remarks | Option exercise | +11,000 | $4.30 | $47K | 11,000 |
| 2021-09-08 | Baeuerle Patrick See Remarks | Sale | −11,000 | $28.45 | $313K | 0 |
| 2021-09-08 | Baeuerle Patrick See Remarks | Option exercise · Stock Option (Right to Buy) | −11,000 | 240,114 | ||
| 2021-09-08 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −10,842 | $29.11 | $316K | 7,688,176 |
| 2021-09-08 | GADICKE ANSBERT Director | Sale | −1,499 | $29.11 | $44K | 250,068 |
| 2021-09-08 | GADICKE ANSBERT Director | Sale | −10,842 | $29.11 | $316K | 7,688,176 |
| 2021-09-07 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −25,067 | $29.04 | $728K | 7,699,018 |
| 2021-09-07 | GADICKE ANSBERT Director | Sale | −3,465 | $29.04 | $101K | 251,567 |
| 2021-09-07 | GADICKE ANSBERT Director | Sale | −25,067 | $29.04 | $728K | 7,699,018 |
| 2021-09-07 | Zawel Leigh See Remarks | Sale | −28,118 | $28.95 | $814K | 65,406 |
| 2021-09-03 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −12,731 | $29.60 | $377K | 7,724,085 |
| 2021-09-03 | GADICKE ANSBERT Director | Sale | −1,760 | $29.60 | $52K | 255,032 |
| 2021-09-03 | GADICKE ANSBERT Director | Sale | −12,731 | $29.60 | $377K | 7,724,085 |
| 2021-09-02 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −15,757 | $29.46 | $464K | 7,736,816 |
Page 17 of 23 · 446 trades